189 related articles for article (PubMed ID: 1895153)
1. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
Henze T
Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
[TBL] [Abstract][Full Text] [Related]
3. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
4. Treatment of myasthenia gravis: focus on pyridostigmine.
Maggi L; Mantegazza R
Clin Drug Investig; 2011 Oct; 31(10):691-701. PubMed ID: 21815707
[TBL] [Abstract][Full Text] [Related]
5. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
7. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
8. Successful desensitization protocol for pyridostigmine in a 12 year old patient with myasthenia gravis.
Kaplan F; Topal E
Turk J Pediatr; 2023; 65(2):326-329. PubMed ID: 37114698
[TBL] [Abstract][Full Text] [Related]
9. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
10. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
12. The use of echothiophate in myasthenia gravis.
Foldes FF; Foldes VM; McNall PG
Clin Pharmacol Ther; 1966; 7(5):620-30. PubMed ID: 5957167
[No Abstract] [Full Text] [Related]
13. Malabsorption of pyridostigmine in patients with myasthenia gravis.
Cohan SL; Dretchen KL; Neal A
Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
[TBL] [Abstract][Full Text] [Related]
14. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
15. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
16. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
Sieb JP; Köhler W
Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
[TBL] [Abstract][Full Text] [Related]
17. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
[TBL] [Abstract][Full Text] [Related]
18. Pyridostigmine levels in myasthenia gravis.
Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
[No Abstract] [Full Text] [Related]
19. Mivacurium chloride and myasthenia gravis.
Seigne RD; Scott RP
Br J Anaesth; 1994 Apr; 72(4):468-9. PubMed ID: 8155454
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis.
Punga AR; Sawada M; Stålberg EV
Muscle Nerve; 2008 Mar; 37(3):300-7. PubMed ID: 18069667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
